TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18451387
Drug: Five weekly
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five weekly intra-articular injections of saline solution
Study: 16824849
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus planned GPIIb/IIIa blockade
Study: 16824849
Drug: Provisional drug
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provisional drug use
Study: 16824849
Drug: Provisional GPIIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provisional GPIIb/IIIa inhibitor
Study: 26289163
Drug: Chronic seton
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic seton drainage with oral 6-mercaptopurine (6MP) for one year
Study: 26289163
Drug: Anti-TNF medication
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF medication with 6MP for one year (seton removal after six weeks)
Study: 23048177
Drug: Standard smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard smoking cessation intervention (individual counseling and nicotine replacement therapies)
Study: 23048177
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapies
Study: 16294574
Drug: Antibiotic ointment
Normalized name: CVS Antibiotic Ointment
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic ointment and dry clean dressing (DCD)
Study: 24449819
Drug: Transendocardial stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transendocardial stem cell injection (TESI) with mesenchymal stem cells
Study: 21950372
Drug: Pregabalin (75mg-300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75mg-300mg twice a day)
Study: 12681871
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (100 microg) every 4 hours for a maximum of two doses
Study: 10382948
Drug: G‐CSF starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF starting on day 8
Study: 10382948
Drug: G‐CSF starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF starting on day 15
Study: 9124979
Drug: Cefpirome administered
Normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome administered by slow intravenous infusion in a daily dose of 2 to 4 g every 12 hours depending on the disease severity.
Study: 9124979
Drug: Cefpirome therapy
Normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome therapy for exacerbated severe chronic purulent bronchitis.
Study: 9124979
Drug: Cefpirome treatment
Normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome treatment for mucoviscidosis.
Study: 1829078
Drug: Teicoplanin and
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin and ceftriaxone combination therapy (arm A)
Study: 1829078
Drug: Tri-antibiotic regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-antibiotic regimen (teicoplanin, ceftriaxone, amikacin) when fever occurred (arm B)
Study: 6871920
Drug: Sustained-release quinidine
Normalized name: quinidine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release quinidine gluconate
Study: 6871920
Drug: Sustained-release quinidine
Normalized name: quinidine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release quinidine sulfate
Study: 29806538
Drug: BAY 1158061
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1158061 (30 mg at 14-day interval)
Study: 29806538
Drug: BAY 1158061
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1158061 (60 mg at 28-day interval)
Study: 29806538
Drug: BAY 1158061
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1158061 (90 mg at 14-day interval)
Study: 26446239
Drug: Ramucirumab in
Normalized name: ramucirumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab in combination with docetaxel
Study: 26446239
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with docetaxel
Study: 19302639
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline washout (30 ml saline)
Study: 17969888
Drug: TCM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM therapy according to syndrome differentiation combined with Western medicine
Study: 17969888
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine by staging
Study: 10858688
Drug: Self-administered glycerine
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered glycerine suppository
Study: 30169547
Drug: 100mg Nimesulide
Normalized name: nimesulide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg Nimesulide immediate, intermediate and slow release tablets
Study: 10651671
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (75 or 100 microg) combined with 5 mg of isobaric bupivacaine
Study: 10651671
Drug: Subcutaneous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous saline solution (control group)
Study: 10651671
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine combined with bupivacaine
Study: 8878142
Drug: Oral supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplements (OS)
Study: 2004961
Drug: 3D treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D treatment planning (19.8 Gy boost of a total 70.2 Gy treatment schedule)
Study: 2004961
Drug: 3D treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D treatment planning
Study: 2004961
Drug: 2D treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2D treatment planning
Study: 15848557
Drug: 720 mg
Normalized name: pancreatin 720 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 mg of oral enteric-coated mycophenolate sodium (E-MPS)
Study: 12669777
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg via 2-hour intravenous infusion every 3 to 4 weeks for 12 months
Study: 12669777
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg via 15-minute intravenous infusion every 3 to 4 weeks for 12 months
Study: 12669777
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 8 mg via 15-minute intravenous infusion every 3 to 4 weeks for 12 months
Study: 12080961
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (microwave thermotherapy with the Dornier Urowave)
Study: 7667816
Drug: Enoxaparin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 20 mg per day for one month
Study: 7667816
Drug: Moroxydine chloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moroxydine chloride, 1200 mg per day for one month
Study: 6969625
Drug: Oral BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BCG immunotherapy
Study: 21702128
Drug: Tropisetron (alpha7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (alpha7 nAchR agonist and 5‐HT3 receptor antagonist)
Study: 18643849
Drug: 4-hour patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hour patch application of PD P 506 A
Study: 18643849
Drug: 2-hour patch
Normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour patch application of PD P 506 A
Study: 18643849
Drug: 1-hour patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour patch application of PD P 506 A
Study: 18643849
Drug: 0.5-hour patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-hour patch application of PD P 506 A
Study: 17536077
Drug: Adjustment for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustment for factors affecting glycemia (age, sex, education, marital status, blood pressure, adiposity, hematocrit, fasting and post-glucose load glucose levels, glucose area under the curve, beta-cell function, insulin resistance)
Study: 15978303
Drug: Cetirizine (10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10-mg tablets once daily)
Study: 12706362
Drug: Boost dose
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boost dose for patients ≤40 years
Study: 10589637
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of levobupivacaine 0.25% and morphine 0.005%
Study: 10589637
Drug: Morphine 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.005%
Study: 10163386
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epinephrine (HDE) - 5, 10, and 15 mg boluses to a total dose of 30 mg
Study: 10163386
Drug: Standard-dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose epinephrine (SDE) - 1.0 mg boluses to a maximum dose of 4 mg
Study: 1678965
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg once a day)
Study: 1678965
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg three times a day)
Study: 6351901
Drug: Oral atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atenolol 25 mg twice daily
Study: 6351901
Drug: Oral atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atenolol 50 mg once daily
Study: 6351901
Drug: Oral atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atenolol 100 mg once daily
Study: 25066012
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod
Study: 20142520
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (LT)
Study: 10535718
Drug: carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: carvedilol 25 mg
Study: 10504599
Drug: Double‐blind intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double‐blind intradermal provocation/neutralization skin tests to food antigens
Study: 1848721
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml 1% mepivacaine with pH raised to 7.25 by adding 4 ml 8.4% NaHCO3
Study: 1848721
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml commercially prepared 1% mepivacaine hydrochloride solution containing 4 ml 0.9% NaCl (pH 6.0)
Study: 31889433
Drug: Mixed hypoxic
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed hypoxic dose protocol (LHTLH)
Study: 25936635
Drug: Propranolol (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (3.3 ± 3.0 mg/kg/day)
Study: 21874537
Drug: Simvastatin 40-80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40-80 mg
Study: 17934877
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with agalsidase alfa infusions for > or = 18 months
Study: 10611140
Drug: Eletriptan (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eletriptan (maximum blood concentration 0.5 microM after therapeutic dose)
Study: 9360003
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg once daily)
Study: 1559314
Drug: Diltiazem (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (4 times daily administration)
Study: 28668558
Drug: Early rehabilitation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rehabilitation (exercise therapy) for 6 to 8 weeks
Study: 20980920
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's Wort (SJW) 300 mg three times a day for 14 days in volunteers
Study: 19526764
Drug: Sanhuang Qingxue
Normalized name: MENTHOL 4.3 g / METHYL SALICYLATE 9.4 g TOPICAL OIL [Shuang Long Pain Relieving Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanhuang Qingxue Yin (SQY) plus conventional Western medical therapy
Study: 19526764
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medical therapy only
Study: 17255240
Drug: Children treated
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children treated with antibiotics
Study: 9706854
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg the first day followed by 100 mg per day
Study: 9706854
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg per day
Study: 9706854
Drug: Doxycycline plus
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline plus ibuprofen scheduled as in groups 1 and 2
Study: 9706854
Drug: Placebo capsule/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule/day (control)
Study: 8572869
Drug: Active antihypertensive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antihypertensive treatment with dihydropyridine felodipine, with a focus on achieving DBP < or = 90 mmHg.
Study: 8572869
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment before randomization.
Study: 30874378
Drug: Suvorexant 20
Normalized name: suvorexant 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant 20 mg/d before bedtime for 2 weeks
Study: 26066780
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus 12 sessions of individual music therapy (n = 15)
Study: 26066780
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment only (n = 15)
Study: 16075184
Drug: All antidepressants
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antidepressants
Study: 12834314
Drug: Extended anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended anticoagulant therapy (6 months for temporary risk factors or 1 year for idiopathic pulmonary embolism)
Study: 12834314
Drug: Discontinue treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue treatment
Study: 12834314
Drug: Discontinue treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue treatment (for idiopathic venous thromboembolism)
Study: 8911976
Drug: Glibenclamide (2.5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (2.5-20 mg)
Study: 1725891
Drug: Nicardipine 40
Normalized name: niCARdipine 40 mg/200 mL-D5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 40 mg, twice daily
Study: 1725891
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg, twice daily
Study: 4002803
Drug: Oral muzolimine
Normalized name: Muzolimine
DrugBank: Muzolimine (DB13801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral muzolimine 120 mg
Study: 26782031
Drug: 150 min/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 min/week of moderate-intensity aerobic exercise and twice-weekly supervised strength training
Study: 24684838
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg quarterly ranibizumab
Study: 24684838
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg quarterly ranibizumab
Study: 24684838
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg monthly ranibizumab
Study: 24684838
Drug: Loading phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading phase of ranibizumab therapy
Study: 22669289
Drug: TAK-875 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 (25, 50, 100, 200, or 400 mg, orally, once daily for 14 days)
Study: 15851648
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with beta-blocker (metoprolol)
Study: 15851648
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with angiotensin-converting enzyme inhibitor (ramipril)
Study: 15851648
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with dihydropyridine calcium channel blocker (amlodipine)
Study: 10087825
Drug: Propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anesthesia with restricted dose of fentanyl (20 micrograms.kg‐1)
Study: 24886409
Drug: High-dose OFS+P
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose OFS+P (30 g/d)
Study: 24886409
Drug: Low-dose OFS+P
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OFS+P (15 g/d)
Study: 24886409
Drug: Control (maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (maltodextrin 15 g/d)
Study: 22914998
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg daily for nine months
Study: 16051946
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy‐General (FACT‐G)
Study: 12477680
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg x kg(-1) of 1% propofol and 3 mg x kg(-1) of 2.5% thiopentone (P/T)
Study: 12477680
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg x kg(‐1) of 1% propofol and 1 mg x kg(‐1) of lidocaine (P/L)
Study: 8728349
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times a day for 6 days
Study: 9853274
Drug: enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 20 mg o.d.
Study: 1857482
Drug: atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50 mg o.d.
Study: 1857482
Drug: chlorthalidone 12.5
Normalized name: chlorthalidone 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorthalidone 12.5 mg o.d.
Study: 6220870
Drug: Erythromycin 1.5
Normalized name: ERYTHROMYCIN 1.5% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 1.5 percent topical solution
Study: 6220870
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1.0 percent topical solution
Study: 31692212
Drug: Medication Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Management Review service (MMR)
Study: 30159666
Drug: IgG anti-HEV
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG anti-HEV antibody testing
Study: 23756585
Drug: Fortified milk
Normalized name: Fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified milk (MG)
Study: 19862820
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg/d on Days 1‐21 of a 28‐day cycle)
Study: 17697909
Drug: Deferasirox (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (5 to 30 mg/kg per day)
Study: 17697909
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine (DFO) (20 to 60 mg/kg per day)
Study: 7614647
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg.kg‐1 before CPB and before declamping of aorta)
Study: 2517323
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg/day orally for 3 days, starting 1 day before X-ray examination)
Study: 1013675
Drug: Metoprolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (3 X 50 mg day)
Study: 31439004
Drug: VIBRA model
Normalized name: doxycycline hyclate Oral Tablet [Vibra-Tabs]
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIBRA model (differentiated ART delivery package with drug refills and follow-ups by trained village health workers, and SMS notifications)
Study: 23538313
Drug: Combined periprostatic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined periprostatic nerve block (PPNB) and perianal‐intrarectal lidocaine‐prilocaine (PILP) cream
Study: 23538313
Drug: Perianal‐intrarectal lidocaine‐prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perianal‐intrarectal lidocaine‐prilocaine (PILP) cream
Study: 12919654
Drug: Glucocorticosteroid at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticosteroid at a low dosage
Study: 12919654
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (with glucocorticosteroid)
Study: 8956920
Drug: Levetiracetam (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (250 mg, 500 mg, 750 mg, 1,000 mg single oral dose; 250 mg b.i.d. for 3-5 days)
Study: 7827348
Drug: Insulin management
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin management (infusion pump or split-dose therapy)
Study: 3294081
Drug: Aluminum-magnesium antacid
Normalized name: ALUMINUM/MAGNESIUM HYDROXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-magnesium antacid (120 mmol/day)
Study: 3294081
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg b.i.d.)
Study: 31016613
Drug: Teriflunomide sodium
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Teriflunomide sodium 10 mg